Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock () or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

InfoGram

New Treatment for Cyanide Poisoning in Phase 1 Clinical Studies

Posted: March 24, 2022

Working to replace IV infusion with intranasal spray

Cyanide is a highly poisonous compound that can enter the body by inhalation, ingestion or contact with skin or eyes. Exposure to cyanide can quickly become fatal.

Why is cyanide a chemical of concern for first responders?

First responders may encounter cyanide in several ways, including as a response to a chemical suicide incident or when cyanide is used as a chemical weapon. A much more common source of cyanide exposure for firefighters is smoke inhalation due to a fire or exposure to the byproducts of combustion after a fire. This is due to the increased use of synthetic polymers in common building materials and furnishings, which release cyanide when they burn.

Why is a new treatment necessary?

When someone is exposed to a toxic amount of cyanide, a rapid medical intervention is required. According to the Occupational Safety and Health Administration, all current Food and Drug Administration-approved treatments for cyanide poisoning require IV infusion for delivery.

Because time is critical to a successful medical intervention for acute cyanide poisoning, a first-line treatment that can be administered more quickly and easily is needed.

How will this new treatment meet this need?

The Department of Health and Human Services’ Biomedical Advanced Research and Development Authority funded research to develop a simple and effective treatment for cyanide poisoning that could be rapidly delivered in a variety of settings. The result, currently being clinically studied, is an intranasal spray intended for administration by first responders and medical personnel following a cyanide incident.

When will this new treatment be available?

Following several years of research by Emergent BioSolutions, in collaboration with Southwest Research Institute, this treatment, using stabilized isoamyl nitrite, is in Phase 1 clinical studies to evaluate the safety and effectiveness of this treatment on humans. Availability will depend on many factors including the study results and regulatory approvals.

This article is based on content in the
March 24, 2022 InfoGram.

View the articles in this InfoGram.

Subscribe to the InfoGram

Explore more articles:

  • Filter:

Featured articles

Infogram
man with monkeypox blisters on his hands
Current Issues
2 firefighters marching in a Pride parade
InfoGram
monkeypox
Infogram
Los Angeles Mayor Eric Garcetti holds a vile of the Moderna COVID-19 vaccination while LAFD firefighters receive the vaccine at Station 4 on Dec. 28.
Current Issues
photo of a man and a woman staring looking at their destroyed home
Current Issues
photo of a woman and man preparing a meal
Current Issues
storm clouds with houses in the foreground
Current Issues
pictograph illustrations
Coffee Break
community members meeting about wildfire projects
Coffee Break
firefighters talking
Current Issues
hoarded items in a home
Coffee Break
firefighters on hose line
Current Issues
home boarded up with clear board
Coffee Break
firefighter using a computer
Coffee Break
binary data with a question mark
Coffee Break
table made up of puzzle pieces
Coffee Break
Plato
Coffee Break
helicopter dropping water on a fire
Coffee Break
meeting of public policy makers
Coffee Break
firefighter addressing meeting